Evaluation of telemedicine medical abortion using a no-test protocol in the Eastern Europe and Central Asian region: Evidence from Ukraine, Uzbekistan, and Azerbaijan
- PMID: 38803127
- DOI: 10.1002/ijgo.15708
Evaluation of telemedicine medical abortion using a no-test protocol in the Eastern Europe and Central Asian region: Evidence from Ukraine, Uzbekistan, and Azerbaijan
Abstract
Objective: To evaluate safety, feasibility, and acceptability of a telemedicine medical abortion service without pre-treatment in-person tests in Ukraine, Uzbekistan, and Azerbaijan.
Methods: We conducted an open-label, prospective, observational clinical study at five clinics in the three countries. Interested and eligible participants scheduled a telemedicine consultation with a study provider by phone or video. Medical abortion pills could be obtained by mail or courier or picked up at the study clinic or a pharmacy. Study providers contacted participants 1 week after mifepristone ingestion to assess abortion outcomes based on symptoms, and 3 weeks later to review the result of an at-home, high-sensitivity, urine pregnancy test. Participants were referred to in-person visit based on symptoms, urine pregnancy test results, or initiative by the participant.
Results: In all, 300 women participated in the study. Almost all participants received medical abortion medications the same day as their first contact with the study clinic, and the majority (n = 297, 99.0%) did not experience any problems receiving them. All except two women (0.67%) followed provider instructions on administration of medications. The majority of participants had a complete abortion without a procedure (Ukraine: n = 115, 95.8%; Uzbekistan: n = 127, 97.7%; Azerbaijan: n = 49, 98.0%), few had in-person visits (Ukraine: n = 30, 25.0%; Uzbekistan: n = 3, 2.3%; Azerbaijan: n = 4, 8.0%), and most were very satisfied or satisfied with the service (Ukraine: n = 116, 96%; Uzbekistan: n = 128, 98%; Azerbaijan: n = 45, 90%). No serious adverse events occurred.
Conclusion: Telemedicine medical abortion using the no-test protocol is safe, feasible and acceptable for women in Ukraine, Uzbekistan, and Azerbaijan.
Keywords: Azerbaijan; Ukraine; Uzbekistan; medical abortion; no‐test; telemedicine.
© 2024 International Federation of Gynecology and Obstetrics.
References
REFERENCES
-
- Hussein J. COVID‐19: what implications for sexual and reproductive health and rights globally? Sex Reprod Health Matters. 2020;28:1746065.
-
- Moreau C, Shankar M, Glasier A, Cameron S, Gemzell‐Danielsson K. Abortion regulation in Europe in the era of COVID‐19: a spectrum of policy responses. BMJ Sex Reprod Health. 2021;47(4):e14.
-
- Erlank CP, Lord J, Church K. Acceptability of no‐test medical abortion provided via telemedicine during Covid‐19: analysis of patient‐reported outcomes. BMJ Sex Reprod Health. 2021;47(4):261‐268.
-
- Beardsworth KM, Doshi U, Raymond E, Baldwin M. Miles and days until medical abortion via TelAbortion versus clinic in Oregon and Washington, USA. BMJ Sex Reprod Health. 2022;48(e1):e38‐e43.
-
- Hyland P, Raymond EG, Chong E. A direct‐to‐patient telemedicine abortion service in Australia: retrospective analysis of the first 18 months. Aust N Z J Obstet Gynaecol. 2018;58(3):335‐340.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
